A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
Stopped Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the anticipated enrollment goal. Justification for this decision is due to slow enrollment and the competitive landscape of the indication.
Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
- DRUG: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
- DRUG: BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Sponsor
Bexion Pharmaceuticals, Inc.
Collaborators